|
C20orf181
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Upregulation in the fibrosis signaling cascade proteins such as fibroblast growth factor (FGF), urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and activation of matrix metalloproteinases (MMPs) are widely associated with the development of myocardial infarction, dilated cardiomyopathy, cardiac fibrosis and heart failure.
|
30980805 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
The direction of effect of all 24 risk factors (including various apolipoproteins, hemoglobin A1<sub>c</sub>, high-sensitivity C-reactive protein, N-terminal pro-brain natriuretic peptide, and tissue plasminogen activator antigen) was concordant for coronary heart disease (CHD, defined as myocardial infarction and CHD death) and ischemic stroke; however, associations were generally stronger with CHD.
|
30371339 |
2018 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the PLATelet inhibition and patient Outcomes (PLATO) trial, we compared spontaneous ischemic events (myocardial infarction or stroke) with spontaneous major bleeding events (PLATO major, Thrombolysis In Myocardial Infarction [TIMI] major, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries [GUSTO] severe) with respect to risk of mortality using time-dependent Cox proportional hazards models.
|
28454837 |
2017 |
|
C20orf181
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate the association of plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (TPA) genes polymorphisms with myocardial infarction and its outcomes in Egyptian patients.
|
25113642 |
2015 |
|
C20orf181
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In some populations, elevated plasma levels of tPA have been associated with myocardial infarction and other cardiovascular diseases.
|
24578379 |
2014 |
|
C20orf181
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in plasminogen activator inhibitor-1 (PAI-1, SERPINE1) and tissue plasminogen activator (tPA, PLAT), such as PAI-1 (-675 4G/5G deletion/insertion) and tPA (Alu insertion/deletion [I/D]), are associated with strokes, myocardial infarctions, bacterial infections and septic shock severity, and trauma.
|
23570848 |
2013 |
|
C20orf181
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of tissue plasminogen activator and plasminogen activator inhibitor polymorphism with myocardial infarction: a meta-analysis.
|
22771216 |
2012 |
|
C20orf181
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Similarly, the genotype frequencies of t-PA I/I, I/D and D/D were not different from the unaffected controls (P>0.05, χ2=1.60), and the risk allele "I" was not found to be associated with MI (P>0.05, χ2=1.35, OR=0.86 (95% CI=0.66-1.11), P>0.05).
|
21082259 |
2011 |
|
C20orf181
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the association between PAI-1-844G/A and 4G/5G polymorphisms and changes in PAI-1 and tissue plasminogen activator (tPA) levels in MI in a Tunisian population.
|
19929406 |
2010 |
|
C20orf181
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To examine interactions among the angiotensin converting enzyme (ACE) insertion/deletion, plasminogen activator inhibitor-1 (PAI-1) 4G/5G, and tissue plasminogen activator (t-PA) insertion/deletion gene polymorphisms on risk of myocardial infarction using data from 343 matched case-control pairs from the Physicians Health Study.
|
15119966 |
2004 |
|
C20orf181
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary our results suggest that the impairment of fibrinolytic activity resulting from elevated levels of PAI-1 antigen and activity and t-PA antigen is an independent variable in CDS associated with the premature occurrence of myocardial infarction in male patients with FH.
|
11253736 |
2001 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial.
|
11479462 |
2001 |
|
C20orf181
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects.
|
9609233 |
1998 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study.
|
9193430 |
1997 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
A case of myocardial infarction with elevated serum Lp(a) concentration and the rare apo(a) phenotype and its successful recanalization using tissue plasminogen activator is reported.
|
8874999 |
1996 |